Lexicon Pharma (LXRX) Tops Q4 EPS by 2c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.10 -2.33%
EPS Growth %: -50.0%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -50.0%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.20), $0.02 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $1.25 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Monolithic Power Systems (MPWR) Reiterated at Buy by Stifel on Reaching $4B Target
- Shoe Station Group Inc. (SHOE) Tops Q2 EPS by 11c ; Offers Guidance
- Driven Brands (DRVN) PT Raised to $18 at Canaccord
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
